Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease

doi:10.3748/wjg.v21.i16.5032

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 16

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9050)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

504

WORD

320

HTML

4672

Figures (1-1)

377

Tables (1-4)

203

Sum=6076

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1139

Download

1835

Sum=2974

Apr 28, 2015 (publication date) through Feb 4, 2025

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Clinical Trial

World J Gastroenterol. Apr 28, 2015; 21(16): 5032-5038
Published online Apr 28, 2015. doi: 10.3748/wjg.v21.i16.5032

Table 1 Demographic and clinical data at baseline (intention-to-treat population) n (%)

	MOX-ST	CLA-ST	P value
Included in ITT analysis	80	81	NS
Age (yr), mean ± SD	59.3 ± 13.1	59.4 ± 13.1	0.235
Gender (male)	34 (42.5)	33 (40.7)	0.773
BMI (kg/m²), mean ± SD	22.9 ± 2.2	22.7 ± 2.9	0.352
Current smoker	11 (13.7)	10 (12.3)	0.385
Alcohol drinking	13 (16.2)	9 (11.1)	0.351
Diabetes	5 (6.2)	8 (9.8)	0.125
Hypertension	19 (23.7)	23 (28.3)	0.407
Previous history of peptic ulcer	12 (15.0)	9 (11.1)	0.348
Endoscopic diagnosis			0.624
Gastritis	70 (87.6)	70 (86.6)
Gastric ulcer	4 (5.0)	5 (6.1)
Duodenal ulcer	1 (1.2)	1 (1.2)
Gastric and duodenal ulcer	1 (1.2)	0 (0.0)
Adenoma	4 (5.0)	4 (4.9)
Dysplasia	0 (0.0)	1 (1.2)
Positive CLOtest	59 (73.7)	62 (76.5)	0.955
H. pylori colonization			0.588
Negative	3 (3.7)	5 (6.1)
Mild	34 (42.5)	36 (44.4)
Moderate	32 (40.0)	24 (29.6)
Marked	11 (13.8)	16 (19.9)
Atrophic change	8 (10.0)	2 (2.4)	0.087
Intestinal metaplasia	10 (12.5)	13 (16.0)	0.761
Drop out	2 (2.5)	4 (4.9)	0.113
Noncompliance	0 (0.0)	0 (0.0)
Follow-up loss	2 (2.5)	4 (4.9)
Discontinued therapy due to adverse events	0 (0.0)	0 (0.0)

MOX-ST: 14-d moxifloxacin-based sequential therapy; CLA-ST: 14-d clarithromycin-based sequential therapy; ITT: Intention-to-treat; SD: Standard deviation; BMI: Body mass index; CLOtest: Rapid urease test; H. pylori: Helicobacter pylori; NS: Not significant; BMI: Body mass index.

Table 2 Helicobacter pylori eradication rates

	MOX-ST	CLA-ST	P value
ITT analysis
Eradication rate	91.3% (73/80)	71.6% (58/81)	0.014
95%CI	86.2%-95.4%	65.8%-77.4%
PP analysis
Eradication rate	93.6% (73/78)	75.3% (58/77)	0.022
95%CI	89.1%-98.1%	69.4%-81.8%

ITT: Intention-to-treat; PP: Per-protocol; CI: Confidence interval; MOX-ST: 14-d moxifloxacin-based sequential therapy; CLA-ST: 14-d clarithromycin-based sequential therapy.

Table 3 Univariate analysis of clinical factors influencing the efficacy

	MOX-ST		CLA-ST
	Eradication rate	P value	Eradication rate	P value
Age (yr)		0.436		0.002
< 60	97.2% (35/36)		81.1% (30/37)
≥ 60	90.4% (38/42)		70.0% (28/40)
Gender		0.383		0.622
Male	91.1% (31/34)		71.8% (23/32)
Female	95.4% (42/44)		77.7% (35/45)
Body mass index		0.651		0.743
< 25	95.2% (20/21)		86.9% (20/23)
≥ 25	92.9% (53/57)		70.3% (38/54)
Smoking		0.585		0.377
(-)	97.0% (65/67)		77.6% (52/67)
(+)	72.7% (8/11)		60.0% (6/10)
Alcohol		0.417		0.082
(-)	96.9% (63/65)		77.9% (53/68)
(+)	76.9% (10/13)		55.5% (5/9)
Diabetes		0.706		0.107
(-)	94.5% (70/74)		76.8% (53/69)
(+)	75.0% (3/4)		62.5% (5/8)
Hypertension		0.322		0.096
(-)	91.6% (55/60)		79.6% (43/54)
(+)	100.0% (18/18)		65.2% (15/23)
History of ulcer		0.454		0.828
(-)	92.5% (62/67)		75.0% (51/68)
(+)	100.0% (11/11)		77.7% (7/9)
Presence of ulcer		0.352		0.076
(-)	92.6% (63/68)		78.7% (52/66)
(+)	100.0% (10/10)		54.5% (6/11)
Positive CLOtest		0.259		0.374
(-)	76.1% (16/21)		63.1% (12/19)
(+)	100.0% (57/57)		79.3% (46/58)
Atrophic change		0.111		0.071
(-)	95.7% (67/70)		76.0% (57/75)
(+)	75.0% (6/8)		50.0% (1/2)
Intestinal metaplasia		0.270		0.322
(-)	95.5% (65/68)		76.5% (49/64)
(+)	80.0% (8/10)		69.2% (9/13)
Bacterial density		0.296		0.507
None	66.7% (2/3)		60.0% (3/5)
Mild	90.6% (29/32)		67.6% (23/34)
Moderate	100.0% (32/32)		78.2% (18/23)
Marked	90.9% (10/11)		93.3% (14/15)
Compliance		NS		NS
Poor	0.0% (0/0)		0.0% (0/0)
Good	93.6% (73/78)		75.3% (58/77)
Adverse events		0.493		0.494
(-)	92.6% (63/68)		77.6% (45/58)
(+)	100.0% (10/10)		68.4% (13/19)

MOX-ST: 14-d moxifloxacin-based sequential therapy; CLA-ST: 14-d clarithromycin-based sequential therapy; CLOtest: Rapid urease test; NS: Not significant.

Table 4 Adverse events and compliance n (%)

Adverse events	MOX-ST(n = 78)	CLA-ST(n = 77)	P value
Bloating/dyspepsia	4 (5.1)	4 (5.3)	0.383
Taste distortion	3 (3.8)	5 (6.4)	0.316
Epigastric discomfort	2 (2.6)	5 (6.4)	0.296
Nausea	1 (1.3)	1 (1.3)	0.505
Abdominal pain	0 (0.0)	1 (1.3)	0.309
Diarrhea	0 (0.0)	3 (3.9)	0.075
Constipation	0 (0.0)	0 (0.0)	NS
Total	10 (12.8)	19 (24.6)	0.038
Compliance, n (%)	78 (100.0)	77 (100.0)	NS

MOX-ST: 14-d moxifloxacin-based sequential therapy; CLA-ST: 14-dclarithromycin-based sequential therapy; NS: Not significant.

Citation: Hwang JJ, Lee DH, Lee AR, Yoon H, Shin CM, Park YS, Kim N. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. World J Gastroenterol 2015; 21(16): 5032-5038
URL: https://www.wjgnet.com/1007-9327/full/v21/i16/5032.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i16.5032